Clinical Trial

Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Available
View on ClinicalTrials.gov →
Summary
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Trial Details
NCT Number NCT07675057
Lead Sponsor Eli Lilly and Company
Conditions Urinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell
Updated on ClinicalTrials.gov 2026-06-30